Search

Your search keyword '"Goldis, Adrian"' showing total 255 results

Search Constraints

Start Over You searched for: Author "Goldis, Adrian" Remove constraint Author: "Goldis, Adrian"
255 results on '"Goldis, Adrian"'

Search Results

1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

2. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

3. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

4. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

5. Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn’s Disease

6. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

7. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

8. Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study

9. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

10. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

11. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

12. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

13. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

14. Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study

15. Acute Kidney Injury after Endoscopic Retrograde Cholangiopancreatography—A Hospital-Based Prospective Observational Study

18. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

19. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

20. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

21. Romanian Guidelines for the Diagnosis and Treatment of GERD-induced Respiratory Manifestations

23. Mo1802 BOWEL DAMAGE AND ITS ASSOCIATION WITH THE DISABILITY INDEX IN PATIENTS WITH RECENTLY DIAGNOSED CROHN'S DISEASE.

24. 548 DISABILITY IN CROHN'S DISEASE PATIENTS AT DIAGNOSIS: FINDINGS FROM THE CROCO (CROHN'S DISEASE COHORT) STUDY

25. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

26. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

27. Risk Factors for Extraintestinal Manifestations in Inflammatory Bowel Diseases - Data from the Romanian National Registry

28. European Registry on Helicobacter pylori management (Hp-EuReg):Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

29. Romanian Guidelines for Nonpharmacological Therapy of IBS

30. MO350ACUTE KIDNEY INJURY RELATED TO ENDOSCOPIC RETROGRADE COLANGIO-PANCREATOGRAPHY IS ASSOCIATED WITH INCREASED INCIDENCE OF IN-HOSPITAL MORTALITY

31. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

32. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

33. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY

34. Sa1895 VALIDATION OF THE LÉMANN INDEX IN CROHN'S DISEASE

35. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

36. sj-pdf-1-ueg-10.1177_2050640620945949 - Supplemental material for The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study

37. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

38. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort:an Epi-IBD study

39. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin:Experience from the European Registry on H pylori management (Hp-EuReg)

40. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up:a population-based study

41. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study

43. Percutaneous Endoscopic Gastrostomy with Jejunal Extension Tube for the Delivery of Levodopa Carbidopa Intestinal Gel: Clinical Practice Guidelines of the Romanian Society of Digestive Endoscopy

45. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

46. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort : an Epi-IBD study

47. Biomaterials in gastroenterology: A critical overview

48. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort:An Epi-IBD study

49. Natural Disease Course of Ulcerative Colitis during the First Five Years of Follow-up in a European Population-based Inception Cohort - An Epi-IBD Study

50. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort:An Epi-IBD study

Catalog

Books, media, physical & digital resources